Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight. At the Cardiometabolic Health Congress ...

Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned itself as a leader in the weight loss industry. Their approach is simple yet effective ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

For example, a 2022 study of tirzepatide (the active ingredient in Mounjaro) prescribed for obesity included people with an average weight of 231 lb. After 18 months, participants on the lowest ...